Detalhe da pesquisa
1.
Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors.
Cancer Invest
; 29(1): 56-61, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21166499